EHA-SWG Scientific Meeting on Granulocytes and Constitutional Marrow Failure Syndromes
The second scientific meeting on EHA-SWG Scientific Meeting on Granulocytes and Constitutional Marrow Failure Disorders and Leukemia Predisposing Genes was held on October 10-12, 2019 in Prague, Czech Republic.
This three-day meeting was organized in collaboration with the EHA Scientific Working Group on Granulocytes and Constitutional Marrow Failure Syndromes, under the guidance of the chair Prof Carlo Dufour. The chair was supported by several co-chairs, Prof Cristina Mecucci, Eleni Papadaki and Kim de Keersmaecker.
“The meeting was very successful in bringing clinicians and scientists in the broad field of congenital bone marrow failure and leukemia predisposition syndromes together. The atmosphere was very interactive, with plenty of time for discussion and setting up collaborations.”
Kim de Keersmaecker (Belgium)
The main objective was to update the participants on the latest achievements in the pathogenesis of granulocyte disorders, constitutional marrow failure syndromes (CMFS), Gaucher disease (GD) and leukemia predisposition genes, on the tools on how to be able to identify and appropriately manage these patients and the newest available treatments.
The knowledge was shared through lectures and round tables. Participants had the opportunity to submit an abstract, of which a number were selected and presented throughout the meeting. The meeting also included contributions tailored to the specific disease area from representatives of patients' associations, and abstract submission with the focus on patients.
“The meeting was well organized and the faculty was very friendly and accommodating. The topics were very targeted and for a specific audience.”
Panagiota Kanellou (Greece)
Discussions focused on the progress in the field of the novel aspects in chronic neutropenia, recent developments in the pathogenesis of “classical CMFS” like ribosome and telomere disorders and Fanconi Anemia took place for the entirety of the meeting. Special attention was devoted to Gaucher disease (GD), the novel area of "Leukemia Predisposition Genes" and how to identify and manage patients carrying these features, the correct timing and indications of stem cell transplantation in congenital neutropenias and in CMFS, and the role of precision medicine in these diseases.
“The place and organization was perfect and on point. The subjects were very informative if you take in account the rarity of the diseases talked about.”
Papadakis Stavros (Greece)
Overall the meeting was attended by 80 participants coming from a wide variety of European and Non-European countries. After the meeting a survey was sent to the participants, the respondents gave an overall rating of 8.2 out of 10 for the meeting.
EHA would like to thank the meeting organizers, the delegates as well as the pharmaceutical companies who supported the meeting, Novartis, and Takeda.